Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
Dominique
D
Breilh
Sarah
S
Djabarouti
Pascale
P
Trimoulet
Brigitte
B
Le Bail
Michel
M
Dupon
Jean-Marie
JM
Ragnaud
Hervé
H
Fleury
Marie-Claude
MC
Saux
Rodolphe
R
Thiébaut
Geneviève
G
Chêne
Didier
D
Neau
D000328:Adult; D000998:Antiviral Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000150:complications*; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a